- Front-line nivolumab+ipilimumab significantly improved health-related QoL vs sunitinib in intermediate- and poor-risk patients with advanced clear cell renal cell carcinoma (RCC).
Why this matters
- QoL data support immunotherapy combination as the new CheckMate of treatment in these patients.
- Post hoc analysis of phase 3, randomized CheckMate 214 trial.
- 847 intermediate-/poor-risk patients with advanced or metastatic clear cell RCC were randomly assigned to receive either nivolumab+ipilimumab (n=425) or sunitinib (n=422).
- Funding: Bristol-Myers Squibb; ONO Pharmaceutical.
- Median follow-up, 25.2 months.
- Patient-reported outcome (PRO) scores were consistently better for nivolumab+ipilimumab.
- At 103 weeks, patients in the nivolumab+ipilimumab vs sunitinib group showed significant improvement in:
- FACT-Kidney Symptom Index-19 (FKSI-19) total score (4.00 vs −3.14; P<.0001>
- Functional Assessment of Cancer Therapy-General (FACT-G) total score (4.77 vs −4.32; P=.0005).
- FKSI-19 (HR, 0.54; 95% CI, 0.46-0.63).
- FACT-G (HR, 0.63; 95% CI, 0.52-0.75).
- EuroQoL 5-dimension 3 level (EQ-5D-3L) visual rating scale scores (HR, 0.75; 95% CI, 0.63-0.89).
- EQ-5D-3L UK utility scores (HR, 0.67; 95% CI, 0.57-0.80).
- Open-label design.